Literature DB >> 12228840

Voriconazole treatment of disseminated paecilomyces infection in a patient with acquired immunodeficiency syndrome.

Craig A Martin1, Sara Roberts, Richard N Greenberg.   

Abstract

We describe a patient with poorly controlled, multidrug-resistant human immunodeficiency virus disease who developed >20 skin lesions caused by Paecilomyces lilacinus. The lesions failed to improve during treatment with oral itraconazole, amphotericin B, and amphotericin B lipid complex but improved during treatment with voriconazole.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12228840     DOI： 10.1086/342302

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

Review 1.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus successfully treated by oral voriconazole and nystatin packing.

Authors:  Ching-Yu Huang; Pei-Lun Sun; Hsiang-Kuang Tseng
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

Review 3.  Pulmonary mycetoma caused by an atypical isolate of Paecilomyces species in an immunocompetent individual: case report and literature review of Paecilomyces lung infections.

Authors:  F Gutiérrez; M Masiá; J Ramos; M Elía; E Mellado; M Cuenca-Estrella
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

Review 4.  Unusual case of cutaneous and synovial Paecilomyces lilacinus infection of hand successfully treated with voriconazole and review of published literature.

Authors:  Maryam Keshtkar-Jahromi; Arthur H McTighe; Keith A Segalman; Annette W Fothergill; Wayne N Campbell
Journal:  Mycopathologia       Date:  2012-04-08       Impact factor: 2.574

5.  Purpureocillium lilacinum as a cause of cavitary pulmonary disease: a new clinical presentation and observations on atypical morphologic characteristics of the isolate.

Authors:  Ziauddin Khan; Suhail Ahmad; Fahad Al-Ghimlas; Sana Al-Mutairi; Leena Joseph; Rachel Chandy; Deanna A Sutton; Josep Guarro
Journal:  J Clin Microbiol       Date:  2012-02-08       Impact factor: 5.948

Review 6.  Use of voriconazole for the treatment of Paecilomyces lilacinus cutaneous infections: case presentation and review of published literature.

Authors:  Ramzy H Rimawi; Yvonne Carter; Thomas Ware; John Christie; Dawd Siraj
Journal:  Mycopathologia       Date:  2013-01-20       Impact factor: 2.574

Review 7.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

9.  Imaging characteristics of disseminated Geosmithia argillacea causing severe diskospondylitis and meningoencephalomyelitis in a dog.

Authors:  Lukas T Kawalilak; Annie V Chen; Greg R Roberts
Journal:  Clin Case Rep       Date:  2015-09-10

10.  Paecilomyces lilacinus fungaemia in an AIDS patient: the importance of mycological diagnosis.

Authors:  Chuan Hun Ding; Mohd Nizam Tzar; Md Mostafizur Rahman; Najihan Abdul Samat Muttaqillah; Shazatul Reza Mohd Redzuan; Petrick Periyasamy
Journal:  Pak J Med Sci       Date:  2014-07       Impact factor: 1.088
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.